Pasar al contenido principal

MAPEO DE LA RED CORTEZA PREFRONTAL - NUCLEOS DEL RAFE SUBYACENTE A LOS TRASTORNOS DEL ESTADO DE ANIMO EN LA ENFERMEDAD DE PARKINSON PARA IDENTIFICAR CIRCUITOS TERAPEUTICOS

PID2022-141700OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Modelling human neuronal catecholaminergic pigmentation in rodents recapitulates age-related neurodegenerative deficits

  • Laguna, Ariadna|||0000-0002-9732-6677
  • Peñuelas, Núria|||0000-0001-6443-9790
  • González Sepúlveda, Marta|||0000-0002-5627-847X
  • Nicolau Vera, Alba|||0000-0002-0836-2802
  • Arthaud, Sébastien|||0000-0001-7271-5468
  • Guillard-Sirieix, Camille|||0000-0002-2645-1892
  • Lorente-Picón, Marina|||0000-0002-3629-9804
  • Compte, Joan|||0000-0001-5447-5122
  • Miquel-Rio, Lluís|||0000-0002-3547-6004
  • Xicoy, Helena|||0000-0001-6641-1222
  • Liu, Jiong
  • Parent, Annabelle|||0000-0002-6195-812X
  • Cuadros, Thais|||0000-0001-6994-2424
  • Romero-Giménez, Jordi|||0000-0002-8459-9895
  • Pujol, Gemma
  • Gimenez-Llort, Lydia|||0000-0002-4091-489X
  • Fort, Patrice|||0000-0003-1211-8631
  • Bortolozzi, Analía|||0000-0002-2069-9192
  • Carballo-Carbajal, Iria|||0000-0002-4403-8006
  • Vila Bover, Miquel|||0000-0002-1352-989X
One key limitation in developing effective treatments for neurodegenerative diseases is the lack of models accurately mimicking the complex physiopathology of the human disease. Humans accumulate with age the pigment neuromelanin inside neurons that synthesize catecholamines. Neurons reaching the highest neuromelanin levels preferentially degenerate in Parkinson's, Alzheimer's and apparently healthy aging individuals. However, this brain pigment is not taken into consideration in current animal models because common laboratory species, such as rodents, do not produce neuromelanin. Here we generate a tissue-specific transgenic mouse, termed tgNM, that mimics the human age-dependent brain-wide distribution of neuromelanin within catecholaminergic regions, based on the constitutive catecholamine-specific expression of human melanin-producing enzyme tyrosinase. We show that, in parallel to progressive human-like neuromelanin pigmentation, these animals display age-related neuronal dysfunction and degeneration affecting numerous brain circuits and body tissues, linked to motor and non-motor deficits, reminiscent of early neurodegenerative stages. This model could help explore new research avenues in brain aging and neurodegeneration. Unlike humans, rodents do not accumulate the brain pigment neuromelanin in catecholamine neurons with age. The transgenic mouse model here presented accumulates neuromelanin and mimics the early physiopathology of Parkinson's disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A molecular convergence in the triad of parkinson's disease, depressive disorder and gut health is revealed by the inflammation-miRNA axis

  • Miquel-Rio, Lluís|||0000-0002-3547-6004
  • Jericó-Escolar, Judith
  • Yanes-Castilla, Claudia
  • Sarriés-Serrano, Unai
  • Paz, Verónica
  • Callado, Luis F.|||0000-0001-9941-012X
  • Meana, J. Javier|||0000-0002-7913-6714
  • Bortolozzi, Analía|||0000-0002-2069-9192
Parkinson's disease (PD) is a multisystem disorder frequently comorbid with non-motor symptoms like depressive disorder (DD) and gastrointestinal (GI) dysfunction. Chronic neuroinflammation and disruption of the gut-brain axis are implicated as shared pathological drivers, but the precise molecular mechanisms connecting these conditions remain elusive. We hypothesized that a common microRNA (miRNA)-mediated inflammatory profile underlies this clinical triad, representing a point of pathological convergence. We analyzed the expression of a panel of inflammatory bowel disease (IBD)-associated miRNAs, key inflammatory markers, and glial response in postmortem brain tissue (dorsolateral prefrontal cortex and caudate nucleus) from patients with PD, DD, and matched healthy controls. To investigate causality and gut-brain axis involvement, two mouse models were used: (i) PD-associated α-synucleinopathy was induced in dorsal raphe serotonin (5-HT) neurons; and (ii) DD-like based on corticosterone (CORT)-induced stress. Mice were assessed for depressive-like behaviors and GI dysmotility, and their brain (medial prefrontal cortex and caudate-putamen) and ileum tissues were analyzed for the same molecular markers. We identified a conserved miRNA pattern in the brains of both PD and DD patients, characterized by the significant downregulation of miR-199a-5p and miR-219a-5p and the upregulation of miR-200a-3p. This dysregulation was strongly associated with a pro-inflammatory state, as evidenced by increased expression of TNFα, IFN-γ, and NFκB1, as well as changes in the glial response. Mice with α-synucleinopathy in the 5-HT system exhibited a depression-like phenotype and reduced intestinal motility, accompanied by increased Iba1 and GFAP signal. Comparable effects were observed in mice subjected to CORT-induced stress. Notably, the same pattern of miRNAs and inflammatory cytokines observed in the human brain was replicated in the brain and ileum of DD-PD-like mice, providing direct evidence of a parallel pathological process spanning the gut-brain axis. This study identifies a specific inflammation-miRNA pathway as a common molecular mechanism connecting the pathophysiology of PD, DD, and gut dysfunction. This pattern represents a critical point of convergence that drives a shared, bidirectional inflammatory cascade along the gut-brain axis. Targeting this miRNA triad could provide a new therapeutic approach for addressing the motor, psychiatric, and GI symptoms of these interconnected disorders simultaneously.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Early synaptic changes and reduced brain connectivity in PD-like mice with depressive phenotype

  • Miquel-Rio, Lluis
  • Jericó-Escolar, Judith
  • Sarriés-Serrano, Unai
  • Yanes-Castilla, Claudia
  • Torres-López, María
  • Argibay, Uxia
  • Paz, Verónica
  • Casal, Carmen
  • Muñoz-Moreno, Emma
  • López-Gil, Xavier
  • Bortolozzi, Analía
Anxiety and depression are common in Parkinson’s disease (PD), affecting quality of life. Aggregates of α-synuclein (α-Syn) are found in serotonergic (5-HT) raphe nuclei early in the disease, but their relationship to brain changes is unclear. We investigated synaptic plasticity, neuronal activity, and functional magnetic resonance imaging (fMRI)-based brain connectivity in a PD-like mouse model with depressive phenotype. AAV-induced human α-Syn accumulation in raphe 5-HT neurons causes progressive synaptic pathology in interconnected brain regions. This is marked by lower MAP-2, PSD95 and higher SV2A, VAMP2, which are key to synaptic structure and function, as confirmed in human brain tissue samples. Abnormalities in Egr-1-dependent neuronal activity and region-specific differences in resting-state functional brain activity were also detected eight weeks post-AAV infusion, before neurodegeneration. This provides evidence for synaptic and fMRI markers associated with α-Syn pathology in emotional brain circuits, and has translational importance for identifying PD patients at risk for depression., This work was supported by MCIU/AEI/FEDER, UE grant (PID2019-105136RB-100, PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033 to A.B.), and AGAUR 2021-SGR-01358, Catalan Government. CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM). We also thank the Spanish Stress Research Network, MCIN/AEI/10.13039/501100011033. U.S.S. is a recipient of a fellowship from the Non- Doctor Researcher Formation Pre-doctoral Program of Basque Government, Spain. U.A. is a recipient of a fellowship from the State Research Agency for the training of predoctoral research personnel (PREP2022-000676) associated to a generation of knowledge project (PID2022-141700OB-I00). The authors would like to thank the staff members of the Biobank of the Clinic Hospital Barcelona - IDIBAPS for their collaboration in the study.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models

  • Franco, Nadia Di
  • Bengoetxea de Tena, Iker
  • Sanchez-Ruiz, Andrea
  • Pereda-Velarde, Alba
  • Enfedaque, Ferran
  • González-Arias, Candela
  • Miquel-Rio, Lluis
  • Bortolozzi, Analía
  • Rodríguez-Puertas, Rafael
  • Costas-Insua, Carlos
  • Molina-Porcel, Laura
  • Vázquez-Oliver, Anna
  • Ozaita Mintegui, Andrés, 1969-
  • Guzmán, Manuel
  • Perea, Gertrudis
  • Ginés, Silvia
Background: Dysregulation of the endocannabinoid system (eCBS) and the loss of CB1 receptors (CB1R) in the basal ganglia are well-established hallmarks of Huntington's disease (HD). As a result, significant research efforts have focused on targeting the eCBS to alleviate motor disturbances associated with the disease. Beyond its role in motor control, the eCBS is a complex signaling network critically involved in regulating learning and memory. Despite this, the potential involvement of eCBS dysfunction in the cognitive decline characteristic of HD, often manifested well before motor dysfunction, has remained largely unexplored. Methods: CB1R expression in the hippocampus was evaluated in both human HD samples and HD mouse models (R6/1 and Hdh models, including both sexes) using Western blotting, immunohistochemistry, and radioligand binding assays. To restore CB1R function, CB1R agonist WIN-55212-2 was systemically administered, or viral vectors encoding CB1R were locally infused into the hippocampus of HD mice. A multidisciplinary approach combining behavioral, biochemical, electrophysiological, and morphological analyses, was employed to investigate the molecular mechanisms underlying the effects of CB1R activation in the context of HD-related cognitive dysfunction. Results: In both human HD samples and HD mouse models, CB1R protein levels were reduced in the hippocampus, accompanied by structural synaptic alterations and impairment in spatial, recognition and working memory. Moreover, hippocampal depolarization-induced suppression of inhibition was significantly disrupted in R6/1 mice. Administration of WIN-55212-2 successfully restored these synaptic and cognitive deficits. Immunohistochemical analysis revealed that the CB1R decrease was specifically localized to GABAergic interneurons within the hippocampus. Notably, targeted restoration of CB1R expression in these interneurons via viral vector delivery was sufficient to rescue hippocampal-dependent memory deficits in HD mice. Conclusion: This study suggests that impaired CB1R function in hippocampal GABAergic interneurons contributes to memory dysfunction in HD., This work was supported by the Spanish Ministerio de Ciencia e Innovación (PID2021-123732OB-I00 to SG, PID2021-125118OB-I00 to MG, PID2019-106579RB-I00, and PID2022-142617NB-I00 to GP, and PID2022-141700OB-I00 to AB funded by MCIN/AEI/ https://doi.org/10.13039/501100011033). Fundació la Marató de TV3 (202013-30-31-32 to SG, MG and GP), AGAUR Generalitat de Catalunya (2021-SGR-01358 to AB and 2021-SGR 01086 to SG) and grants to R. R.-P. rom the Basque Government IT1454-22 to the "Neurochemistry and Neurodegeneration" consolidated research group; Instituto de Salud Carlos III through the project PI20/00153 (co-funded by European Regional Development Fund "A way to make Europe") and by BIOEF through the project BIO22/ALZ/010 funded by Eitb Maratoia. A P-V is the recipient of a PRE2022-101764 fellowship (PID2021-123732OB-I00). I.B.d.T. is the recipient of an Investigo fellowship funded by the European Union-Next Generation EU.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modelling human neuronal catecholaminergic pigmentation in rodents recapitulates age-related neurodegenerative deficits

  • Laguna, Ariadna
  • Peñuelas, Núria
  • Gonzalez-Sepulveda, Marta
  • Nicolau, Alba
  • Arthaud, Sébastien
  • Guillard-Sirieix, Camille
  • Lorente-Picón, Marina
  • Compte, Joan
  • Miquel-Rio, Lluís
  • Xicoy, Helena
  • Liu, Jiong
  • Parent, Annabelle
  • Cuadros, Thais
  • Romero-Giménez, Jordi
  • Pujol, Gemma
  • Giménez-Llort, Lydia
  • Fort, Patrice
  • Bortolozzi, Analía
  • Carballo-Carbajal, Iria
  • Vila, Miquel
One key limitation in developing effective treatments for neurodegenerative diseases is the lack of models accurately mimicking the complex physiopathology of the human disease. Humans accumulate with age the pigment neuromelanin inside neurons that synthesize catecholamines. Neurons reaching the highest neuromelanin levels preferentially degenerate in Parkinson's, Alzheimer's and apparently healthy aging individuals. However, this brain pigment is not taken into consideration in current animal models because common laboratory species, such as rodents, do not produce neuromelanin. Here we generate a tissue-specific transgenic mouse, termed tgNM, that mimics the human age-dependent brain-wide distribution of neuromelanin within catecholaminergic regions, based on the constitutive catecholamine-specific expression of human melanin-producing enzyme tyrosinase. We show that, in parallel to progressive human-like neuromelanin pigmentation, these animals display age-related neuronal dysfunction and degeneration affecting numerous brain circuits and body tissues, linked to motor and non-motor deficits, reminiscent of early neurodegenerative stages. This model could help explore new research avenues in brain aging and neurodegeneration., This research was funded by: Aligning Science Across Parkinson’s through The Michael J. Fox Foundation for Parkinson’s Research, USA (ASAP-020505 to M.V.); The Michael J. Fox Foundation for Parkinson’s Research, USA (MJFF-007184 and MJFF-001059 to M.V.); Ministry of Science and Innovation (MICINN), Spain (PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033 to A.B. and PID2020-116339RB-I00 to M.V.); EU Joint Program Neurodegenerative Disease Research (JPND), Instituto de Salud Carlos III, EU/Spain (AC20/00121 to MV): La Caixa Bank Foundation, Spain (INPhINIT fellowship, code LCF/BQ/DI18/1166063 to J.C.; Junior Leader Fellowship LCF/BQ/PR19/11700005 to A.L.; Health Research Grant, ID 100010434 under the agreement LCF/PR/HR17/52150003 to MV); Parkinson’s U.K. (to M.V.); Research grants from Association France Parkinson and Fondation Neurodis (to P.F.); China Scholarship Council (CSC; no. 202008620080) to J.L.; Ministry of Economy and competitiveness (MINECO), Spain with co-funding from FEDER (E.U.) (SAF2015-73997-JIN to A.L.); Ministry of Economy and competitiveness (MINECO), Spain (BES-2017-080191 to N.P.). We are grateful to: the Neurological Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS (Barcelona, Spain) and the Biobanco en Red de la Región de Murcia-BIOBANC-MUR (Murcia, Spain) for human sample procurement; Sandra Lope-Piedrafita (UAB, Barcelona, Spain) for technical assistance in the performance of MRI experiments in rodents; the Mesoscopic Imaging Facility (MIF) at the European Molecular Biology Laboratory (EMBL) (Barcelona) for support in brain clarification procedures; Sandra Mancilla from the Unit 20 of CIBER in Bioengineering, Biomaterials & Nanomedicne (CIBER-BBN) at VHIR (Barcelona, Spain) and Beatriz Rodríguez-Galván (VHIR) for assistance in histological processing; Ignasi Sahún from the Phenotyping Unit at Parc Científic de Barcelona (Barcelona, Spain), Guillem Colell and Anna Pujol from the Laboratory Animal Service at VHIR, Lidia Castillo-Mariqueo and Daniela Marin-Pardo from the Translational Behavioral Neuroscience Lab at UAB and Pamela Dominguez at VHIR for assistance in animal behavior; Eliana Markidi for immunoblot analyses and laboratory assistance; Alex Rovira (Neuroradiology section, Vall d’Hebron Hospital, Barcelona, Spain) for providing the human NM-MRI images; Ellen Gelpi (Neurological Tissue Bank, Hospital Clínic-IDIBAPS, Barcelona, Spain & Institute of Neurology, Medical University of Vienna, Austria) for providing the human autopsy images; Dr. Takafumi Hasegawa (Department of Neurology, Tohoku University School of Medicine, Sendai, Japan) for kindly providing the TYR plasmid; Dr. Jin Son and Dr. José López-Barneo from Hospital Virgen del Rocío (Sevilla, Spain) for kindly providing the rat TH promoter plasmid; Prof. Kazumasa Wakamatsu and Prof. Shosuke Ito (Fujita Health University, Aichi, Japan) for kindly donating the 5SCD and 5SCDA standards; Professor Gary Miller (Columbia University, USA) for kindly donating the VMAT2 antibody. All diagrams and schematic experimental plans were created with BioRender.com. For the purpose of open access, the author has applied a CC-BY 4.0 public copyright license to all Author Accepted Manuscripts arising from this submission., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

SAMson: an automated brain extraction tool for rodents using SAM

  • Panadero Soler, Daniel
  • Kotb Selim, Mohamed
  • Martínez-Tazo, Patricia
  • Muñoz-Moreno, Emma
  • Ramos-Cabrer, Pedro
  • López-Larrubia, Pilar
  • De Santis, Silvia
  • Canals, Santiago
  • Pertusa, Antonio
[Description of methods used for collection/generation of data] D1: Images acquired on a 7-T scanner (Bruker, BioSpec 70/30, Ettlingen, Germany) using a T2-weighted RARE (Rapid Acquisition with Relaxation Enhancement) sequence. D2: Images acquired on a 7-T scanner (Bruker, BioSpec 70/30, Ettlingen, Germany) equipped with an actively shielded gradient system using a T2-weighted sequence. D3: Images acquired on a 11.4-T MRI scanner (Bruker BioSpec USR 117/16, Ettlingen, Germany) using a T2-weighted RARE sequence., [Methods for processing the data] Panadero Soler, Daniel; Kotb Selim, Mohamed; Martínez-Tazo, Patricia; Muñoz-Moreno, Emma; Ramos-Cabrer, Pedro; López-Larrubia, Pilar; De Santis, Silvia; Canals, Santiago; Pertusa, Antonio; 2025; SAMson: an automated brain extraction tool for rodents using SAM [Dataset]; BioRxiv; https://doi.org/10.1101/2024.03.07.583982, S.C. acknowledges support from PCI2024-153491 funded by MICIU /AEI /10.130 39/501100011033 and UE, PID2021-128158NB-C21 funded by MICIU/10.13039/ 50110 0011033 and FEDER, UE, CEX2021-001165-S funded by MICIU/AEI /10.13039/50110 0011033 and Excellence Grant CIPROM/2022/15 and INVESTIGO INVEST/2022/396 funded by the Generalitat Valenciana and Next Generation EU. S.D.S. was supported by the the Spanish Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación (PID2021-128909NA-I00 and CNS2023-14488 ), by the Programs for Centres of Excellence in R\&D Severo Ochoa (CEX2021-001165-S), and by the Generalitat Valenciana through a Subvencion para la contratación de investigadoras e investigadores doctores de excelencia 2021 (CIDEGENT/2021/015) and by a Fundación Pasqual Maragall Research Programme (2024 call). P.L-L. was funded by grant PID2021-122528OB-I00 funded by MICIU/AEI/10.13039/501100011033/FEDER, UE. Some of the mice used in this study were generated in the project funded by MCIU/AEI/FEDER, UE grants PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033 and CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM, Bortolozzi A). In addition, the funding sources acknowledged in: 1) Mateu-Bosch A, Segur-Bailach E, Muñoz-Moreno E, Barallobre MJ, Arbonés ML, Gea-Sorlí S, et al. Systemic delivery of AAV-GCDH ameliorates HLDinduced phenotype in a glutaric aciduria type I mouse model. Molecular Therapy - Methods & Clinical Development. 2024;32(3):101276. Available from: https://www.sciencedirect.com/science/article/pii/S2329050124000925. and 2) Haddad-Tóvolli R, Ramírez S, Muñoz-Moreno E, Milà-Guasch M, Miquel-Rio L, Pozo M, et al. Food craving-like episodes during pregnancy are mediated by accumbal dopaminergic circuits. Nature Metabolism. 2022 Apr;4(4):424-34. Available from: https://doi.org/10.1038/s42255-022-00557-1., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001165-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

SAMson: an automated brain extraction tool for rodents using SAM

  • Panadero Soler, Daniel
  • Kotb Selim, Mohamed
  • Martínez-Tazo, Patricia
  • Muñoz-Moreno, Emma
  • Ramos-Cabrer, Pedro
  • López-Larrubia, Pilar
  • De Santis, Silvia
  • Canals, Santiago
  • Pertusa, Antonio
Accurate brain extraction is a critical step in the analysis of rodent head magnetic resonance imaging (MRI) data. However, current methods often encounter difficulties in handling the diverse range of imaging setups, resolutions, and experimental conditions commonly found in this field. SAMson (SAM for Segmentation Of Neuroimages) is an automated tool based on the Segment Anything Model (SAM), designed for robust rodent brain extraction. It integrates a bounding box generator and a mask prediction pipeline, offering fully automated and semi-automated modes to address varying experimental complexities. SAMson has been evaluated using three multi-centre rodent MRI datasets annotated at the pixel level, differing in acquisition parameters, resolution, and animal age groups. The tool demonstrates superior performance to existing methods (BET, RBM, BEN) in terms of segmentation accuracy, with Jaccard indices exceeding 90% across datasets. Its semi-automated mode is particularly effective in challenging scenarios such as low-resolution images and cases requiring refined mask precision. By identifying errors at the individual slice level, SAMson enables rapid and targeted corrections, advancing translational neuroscience by supporting large-scale research workflows. The curated data can be downloaded from https://doi.org/10.20350/digitalCSIC/17000, and the code is available at https://github.com/CanalsLab/SAMson., S.C. acknowledges support from PCI2024-153491 funded by MICIU /AEI /10.130 39/501100011033 and UE, PID2021-128158NB-C21 funded by MICIU/10.13039/ 50110 0011033 and FEDER, UE, CEX2021-001165-S funded by MICIU/AEI /10.13039/50110 0011033 and Excellence Grant CIPROM/2022/15 and INVESTIGO INVEST/2022/396 funded by the Generalitat Valenciana and Next Generation EU. S.D.S. was supported by the the Spanish Ministerio de Ciencia e Innovacion, Agencia Estatal de Investigaci´on (PID2021-128909NA-I00 and CNS2023-14488 ), by the Programs for Centres of Excellence in R&D Severo Ochoa (CEX2021-001165-S), and by the Generalitat Valenciana through a Subvencion para la contratacion de investigadoras e investigadores doctores de excelencia 2021 (CIDEGENT/2021/015) and by a Fundacion Pasqual Maragall Research Programme (2024 call). P.L-L. was funded by grant PID2021-122528OB-I00 funded by MICIU/AEI/10.13039/501100011033/FEDER, UE. Some of the mice used in this study were generated in the project funded by MCIU/AEI/FEDER, UE grants PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033 and CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM, Bortolozzi A)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001165-S)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

MiRNAs and extracellular vesicles in psychiatry: Potential biomarkers, therapeutic advances, and animal models

  • Miquel-Rio, Lluís
  • Anmella, Gerard
  • Bortolozzi, Analía
In their perspective article Opportunities for advancing miRNA research in psychiatry, Navarro-Flores and Heilbronner highlight the potential of miRNAs as biomarkers and therapeutic targets in psychiatry (Navarro-Flores and Heilbronner, n.d.). Almost 10 years after the first review on the role of miRNAs in psychiatric disorders (Issler and Chen, 2015), the authors provide updated information on new approaches in the investigation of these molecules. They focus on new insights into the regulatory mechanisms of miRNA-dependent transcripts and their downstream functional effects, as well as spatiotemporal dynamics, epidemiological factors (e.g., gender and ethnicity), integration with multi-omics approaches, and the need for bioinformatics standardization and clinical translation. Based on their discussion, we would like to highlight other key areas that we believe are and will continue to be fundamental for the advancement of miRNA research in psychiatry., We thank the support of MCIU/AEI/FEDER, UE grant PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033; Fundación La Marató TV3 (202207); AGAUR 2021-SGR-01358, Government of Catalonia; and the Translational Research Programme for Brain Disorders, IDIBAPS. We also thank the Spanish Ministry of Health financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Social Fund+ (ESF+) (JR23/00050, MV22/00058, CM21/00017); the ISCIII (PI21/00340, PI21/00169); the Milken Family Foundation (PI046998); the Fundació Clínic per a la Recerca Biomèdica (FCRB) - Pons Bartan 2020 grant (PI04/6549), the Sociedad Española de Psiquiatría y Salud Mental (SEPSM); the Fundació Vila Saborit; and the Societat Catalana de Psiquiatria i Salut Mental (SCPiSM). GA is supported by a Juan Rodés 2023 grant (JR23/00050), a Rio Hortega 2021 grant (CM21/00017) and Acción Estratégica en Salud - Mobility (M-AES) fellowship (MV22/00058), from the Spanish Ministry of Health financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the Fondo Social Europeo Plus (FSE+)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impaired unfolded protein response, BDNF and synuclein markers in postmortem dorsolateral prefrontal cortex and caudate nucleus of patients with depression and Parkinson's disease

  • Sarries-Serrano, Unai
  • Miquel-Rio, Lluís
  • Santana, Noemí
  • Paz, Verónica
  • Sancho-Alonso, María
  • Callado, Luis F.
  • Meana, J. Javier
  • Bortolozzi, Analía
Major depressive disorder (MDD) is characterized by significant impairment in social, emotional, and cognitive functioning. Its precise pathophysiology remains poorly understood. Alterations in protein homeostasis and some misfolded proteins have been identified within the brains of patients diagnosed with neuropsychiatric disorders. In contrast to neurodegenerative processes such as Parkinson's disease (PD), where the accumulation of aggregated α-synuclein (α-Syn) protein is a primary cause of significant neuronal loss, altered proteostasis in MDD may result in loss-of-function effects by modifying synaptic neuroplasticity. Moreover, aberrant activation of endoplasmic reticulum (ER) pathways may intensify the pathological alterations due to altered proteostasis. In this study, dorsolateral prefrontal cortex (dlPFC) and caudate nucleus from MDD patients and non-psychiatric controls were used. Postmortem samples of same brain areas from PD patients (Braak 2-3 and 5-6) and controls were also included. Protein levels of ER and unfolded protein response (UPR), synucleins (α-, β- and γ-Syn), and brain-derived neurotrophic factor (BDNF) were measured by Western-Blot. Phospho-eIF2α/eIF2α ratio was increased in the dlPFC and caudate nucleus of MDD and PD patients compared to their respective controls. Brain area-dependent changes in BiP and GRP94 levels were also found. We further detected accumulation of immature BDNF precursors and opposite changes in α- and β-Syn levels in the dlPFC of MDD and PD patients compared to controls. Our findings suggest that alterations in proteostasis contribute to the pathophysiology of MDD, as previously described in PD. A deeper understanding of the pathways involved will identify other candidate proteins and new targets with therapeutic potential., This work has been funded by MCIU/AEI/FEDER, an EU grant (PID2019-105136RB-100, PID2022-141700OB-I00, MCIN/AEI/10. 13039/501100011033 to AB), and AGAUR 2021-SGR-01358, Government of Catalonia, Basque Government (IT1512/22), CB/07/09/0034 and CB/07/09/0008 Centre for Biomedical Research in Mental Health Network (CIBERSAM). We would also like to thank the Spanish Network for Research on Stress, MCIN/AEI/10.13039/501100011033. USS has received a grant from the Training Programme for Non-Doctoral Pre-doctoral Researchers of the Basque Government, Spain. MSA has a Margarita Salas Scholarship (MS21-132) from the University of Valencia (reclassification of the Spanish University System of the Ministry of Universities of the Government of Spain, financed by the European Union, Next Generation EU). The authors would like to thank the staff members of the Basque Institute of Legal Medicine for their collaboration in the study., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Early synaptic changes and reduced brain connectivity in PD-like mice with depressive phenotype

  • Miquel-Rio, Lluís
  • Jericó-Escolar, Judith
  • Sarries-Serrano, Unai
  • Yanes-Castilla, Claudia
  • Torres-López, María
  • Argibay, Uxia
  • Paz, Verónica
  • Casal, Carme
  • Muñoz-Moreno, Emma
  • López-Gil, Xavier
  • Bortolozzi, Analía
Anxiety and depression are common in Parkinson’s disease (PD), affecting quality of life. Aggregates of α-synuclein (α-Syn) are found in serotonergic (5-HT) raphe nuclei early in the disease, but their relationship to brain changes is unclear. We investigated synaptic plasticity, neuronal activity, and functional magnetic resonance imaging (fMRI)-based brain connectivity in a PD-like mouse model with depressive phenotype. AAV-induced human α-Syn accumulation in raphe 5-HT neurons causes progressive synaptic pathology in interconnected brain regions. This is marked by lower MAP-2, PSD95 and higher SV2A, VAMP2, which are key to synaptic structure and function, as confirmed in human brain tissue samples. Abnormalities in Egr-1-dependent neuronal activity and region-specific differences in resting-state functional brain activity were also detected eight weeks post-AAV infusion, before neurodegeneration. This provides evidence for synaptic and fMRI markers associated with α-Syn pathology in emotional brain circuits, and has translational importance for identifying PD patients at risk for depression., This work was supported by MCIU/AEI/FEDER, UE grant (PID2019-105136RB-100, PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033 to A.B.), and AGAUR 2021-SGR-01358, Catalan Government. CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM). We also thank the Spanish Stress Research Network, MCIN/AEI/10.13039/501100011033. U.S.S. is a recipient of a fellowship from the Non- Doctor Researcher Formation Pre-doctoral Program of Basque Government, Spain. U.A. is a recipient of a fellowship from the State Research Agency for the training of predoctoral research personnel (PREP2022-000676) associated to a generation of knowledge project (PID2022-141700OB-I00). The authors would like to thank the staff members of the Biobank of the Clinic Hospital Barcelona - IDIBAPS for their collaboration in the study., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models

  • Di Franco, Nadia
  • Bengoetxea de Tena, Iker
  • Sanchez-Ruiz, Andrea
  • Pereda-Velarde, Alba
  • Enfedaque, Ferran
  • Gónzalez-Arias, Candela
  • Rio, Lluis Maria Miquel
  • Bortolozzi, Analía
  • Rodriguez-Puertas, Rafael
  • Costas-Insua, Carlos
  • Molina-Porcel, Laura
  • Vazquez-Oliver, Anna
  • Ozaita, Andres
  • Guzmán, Manuel
  • Perea, Gertrudis
  • Ginés, Silvia
Dysregulation of the endocannabinoid system (eCBS) and the loss of CB1 receptors (CB1R) in the basal ganglia are well-established hallmarks of Huntington's disease (HD). As a result, significant research efforts have focused on targeting the eCBS to alleviate motor disturbances associated with the disease. Beyond its role in motor control, the eCBS is a complex signaling network critically involved in regulating learning and memory. Despite this, the potential involvement of eCBS dysfunction in the cognitive decline characteristic of HD, often manifested well before motor dysfunction, has remained largely unexplored., This work was supported by the Spanish Ministerio de Ciencia e Innovación (PID2021-123732OB-I00 to SG, PID2021-125118OB-I00 to MG, PID2019-106579RB-I00, and PID2022-142617NB-I00 to GP, and PID2022-141700OB-I00 to AB funded by MCIN/AEI/ https://doi.org/10.13039/501100011033). Fundació la Marató de TV3 (202013-30-31–32 to SG, MG and GP), AGAUR Generalitat de Catalunya (2021-SGR-01358 to AB and 2021-SGR 01086 to SG) and grants to R. R.-P. from the Basque Government IT1454-22 to the “Neurochemistry and Neurodegeneration” consolidated research group; Instituto de Salud Carlos III through the project PI20/00153 (co-funded by European Regional Development Fund “A way to make Europe”) and by BIOEF through the project BIO22/ALZ/010 funded by Eitb Maratoia. A P-V is the recipient of a PRE2022-101764 fellowship (PID2021-123732OB-I00). I.B.d.T. is the recipient of an Investigo fellowship funded by the European Union-Next Generation EU., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A molecular convergence in the triad of parkinson's disease, depressive disorder and gut health is revealed by the inflammation-miRNA axis

  • Miquel-Rio, Lluís
  • Jericó-Escolar, Judith
  • Yanes-Castilla, Claudia
  • Sarries-Serrano, Unai
  • Paz, Verónica
  • Callado, Luis F.
  • Meana, J. Javier
  • Bortolozzi, Analía
Parkinson's disease (PD) is a multisystem disorder frequently comorbid with non-motor symptoms like depressive disorder (DD) and gastrointestinal (GI) dysfunction. Chronic neuroinflammation and disruption of the gut-brain axis are implicated as shared pathological drivers, but the precise molecular mechanisms connecting these conditions remain elusive. We hypothesized that a common microRNA (miRNA)-mediated inflammatory profile underlies this clinical triad, representing a point of pathological convergence., This work was supported by MCIU/AEI/FEDER, UE grant (PID2022-141700OB-I00, MCIN/AEI/https://doi.org/10.13039/501100011033 to AB), Fundació La Marató de TV3 and Generalitat de Catalunya (202207 to AB), AGAUR 2021-SGR-01358 Government of Catalonia, and Basque Government (IT1512/22). We also thank the Spanish Stress Research Network, MCIN/AEI/https://doi.org/10.13039/501100011033 and CB/07/09/0034 and CB/07/09/0008 Centre for Biomedical Research in Mental Health Network (CIBERSAM). JJE is a recipient of a predoctoral fellowship (2025 FI-AGAUR) from the Catalan Government (AGAUR, Generalitat de Catalunya). CYC is a recipient of a predoctoral fellowship (2025 PIP-UAB) from the Autonomous University of Barcelona (UAB). USS is a recipient of a grant from Pre-doctoral Program for the Non-Doctoral Researchers of the Basque Government, Spain. The authors would like to thank the staff of the Basque Institute of Legal Medicine and the Biobank of the Hospital Clinic-IDIBAPS for their collaboration in the study., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New insights into the effects of serotonin on Parkinson's disease and depression through its role in the gastrointestinal tract

  • Sancho-Alonso, María
  • Sarries-Serrano, Unai
  • Miquel-Rio, Lluís
  • Yanes Castilla, Claudia
  • Paz, Verónica
  • Meana, José Javier
  • Perello, Mario
  • Bortolozzi, Analía
Neuropsychiatric and neurodegenerative disorders are frequently associated with gastrointestinal (GI) co-pathologies. Although the central and enteric nervous systems (CNS and ENS, respectively) have been studied separately, there is increasing interest in factors that may contribute to conditions affecting both systems. There is compelling evidence that serotonin (5-HT) may play an important role in several gut-brain disorders. It is well known that 5-HT is essential for the development and functioning of the CNS. However, most of the body's 5-HT is produced in the GI tract. A deeper understanding of the specific effects of enteric 5-HT on gut-brain disorders may provide the basis for the development of new therapeutic targets. This review summarizes current data focusing on the important role of 5-HT in ENS development and motility, with particular emphasis on novel aspects of 5-HT signaling in conditions where CNS and ENS comorbidities are common, such as Parkinson's disease and depressive disorders., This work was supported by MCIU/AEI/FEDER, UE grants (PID2019-105136RB-100, PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033 to AB) and AGAUR 2021-SGR-01358, Catalan Government. CB/07/09/0034 and CB/07/09/0008 Center for Networked Biomedical Research on Mental Health (CIBERSAM). USS is a recipient of a fellowship from the Non-Doctor Researcher Formation Pre-doctoral Program of Basque Government, Spain. MSA has a Margarita Salas Grant (MS21-132) from the University of Valencia (requalification of the Spanish University System of the Ministry of Universities of the Government of Spain, financed by the European Union, Next Generation EU). Figures 1 and 3 were generated using online application “created with BioRender.com”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Overexpression of ¿-Synuclein in the prefrontal cortex induces an anxious phenotype and changes in synaptic plasticity in a female mouse model of Parkinson's disease

  • Argibay, Uxia
  • Garcia-Chavira, M.
  • Paz, Verónica
  • Yanes-Castilla, Claudia
  • Miquel-Rio, Lluís
  • Bortolozzi, Analía
Trabajo presentado en el I Congreso Internacional de la Red Española de Investigación en Estrés, celebrado en Bilbao del 29 al 31 de enero de 2025, Grant PID2022-141700OB-I00 and Spanish Stress Research Network Grant RED2022-134191-T funded by MCIN/AEI/ 10.13039/501100011033; AGAUR 2021-SGR-01358, Catalan Government; U.A. is a recipient of a fellowship from the State Research Agency for the training of predoctoral research personnel (PREP2022-000676) associated to a generation of knowledge project (PID2022-141700OB-I00).M.G.C. is a recipient of a PITAAE fellowship from the UNAM and the DGECI., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The PADRIS-PRESTO cohort: A comprehensive population-based study on mental health in Catalonia

  • De Prisco, Michele
  • Oliva, Vincenzo
  • Fico, Giovanna
  • Mas, Ariadna
  • Valenzuela-Pascual, Clàudia
  • Montejo, Laura
  • Bort, Marta
  • Sommerhoff, Constanza
  • Bortolozzi, Analía
  • Miquel-Rio, Lluís
  • Vilella, Elisabet
  • Forte, Maria Florencia
  • Fortea, Lydia
  • Fernández, Tabatha
  • Giménez-Palomo, Anna
  • Sague Vilavella, Maria
  • Madero, Santiago
  • Llorca Bofí, Vicent
  • Bioque, Miquel
  • Grande, Iria
  • Murru, Andrea
  • Pacchiarotti, Isabella
  • Cavero, Myriam
  • Blanch, Jordi
  • Viñas-Bardolet, Clara
  • Aparicio-Nogué, Vicenç
  • Martínez-Cerdá, Juan Francisco
  • Parellada, Eduard
  • Martínez-Arán, Anabel
  • Radua, Joaquim
  • Vieta, Eduard
  • Hidalgo-Mazzei, Diego
  • Anmella, Gerard
Mental disorders affect nearly 970 million people worldwide, impacting individuals and healthcare systems. Large population databases offer insights often unattainable in smaller studies, but their findings may not always generalize across diverse regions. To address this, we introduce a European cohort from Catalonia, Spain, allowing for comparisons between individuals with mental disorders and the general population., The PRESTO project was supported by the Fundació Clínic per a la Recerca Biomèdica through the Pons Bartran 2020 grant (PI046549); the Spanish Foundation for Psychiatry and Mental Health, the Spanish Psychiatric Society, and the Spanish Society of Biological Psychiatry (PI046813); the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) – PANDÈMIES 2020 grant (2020PANDE00081), Generalitat de Catalunya; the Ministerio de Sanidad through the Pla Director de Salut Mental i Addiccions and the Direcció General de Planificació i Recerca en Salut, Departament de Salut, Generalitat de Catalunya; and by the Ministerio de Ciencia, Innovación y Universidades (MCIN) and the Agencia Estatal de Investigación (AEI, project TED2021-131999BI00, Strategic Projects Oriented to the Ecological Transition and the Digital Transition 2021), with funding from the European Union NextGenerationEU/PRTR. MDP is supported by the Translational Research Programme for Brain Disorders, IDIBAPS. VO is supported by a Rio Hortega 2024 grant (CM24/00143) from the Spanish Ministry of Science, Innovation and Universities financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the Fondo Social Europeo Plus (FSE+). CVP is supported by a FPU grant for University Teaching Training (FPU23/01555) from the Spanish Ministry of Science, Innovation, and Universities and would like to thank the Ministry for its support. MBo thanks the support of a Marató-TV3 Foundation grant 202230-31. AB thanks the support MCIU/AEI/FEDER, UE grant (PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033); Spanish Stress Research Network, MCIN/AEI /10.13039/501100011033; and Fundación La Marató-TV3 and Catalan Government (Grant 202207). EVil thanks the support of the Catalan Agency of Research and Universities (2021SGR01065). MFF received the support of “Contratos predoctorales de formación en investigación en salud" (PFIS22) (FI22/00185) from the Instituto de Salud Carlos III (ISCIII) with European funds from the Recovery, Transformation and Resilience Plan, by virtue of the Resolution of the Directorate of the Carlos III Health Institute, O.A., M.P. of December 14, 2022, granting Predoctoral Research Training Contracts in Health (PFIS Contracts). Funded by the European Union Next Generation EU. She has also been granted by M-AES mobility fellowship (MV24/00050). SM has received support from the “Fundacio Clinic de Recerca Biomedica” through the Emili Letang-Josep Font Scholarship program. VLB is supported by a Rio Hortega 2024 grant (CM24/00074) from the Spanish Ministry of Science, financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the Fondo Social Europeo Plus (FSE+). MBi thanks the support from the Spanish Ministry of Health, Instituto de Salud Carlos III (PI20/01066), Fundació La Marató de TVV3 (202206-30-31), and the Pons-Bartran legacy (FCRB_IPB1_2023). AMA thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI21/00787, PI24/00432), integrated into the Plan Nacional de I+D+I and co-financed by the Instituto de Salud Carlos III -Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme, Generalitat de Catalunya; La Marató-TV3 Foundation grants 202235 33. JR thanks the support of the Spanish Ministry of Science, Innovation and Universities (CPII19/00009, PI22/00261), integrated into the Plan Nacional de I + D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and the Instituto de Salud Carlos III; and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021-SGR-01128). EVie thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI21/00787, PI24/00432) integrated into the Plan Nacional de I+D+I and co-financed by the Instituto de Salud Carlos III -Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme, Generalitat de Catalunya; La Marató-TV3 Foundation grants 202234-30; the European Union Horizon 2020 research and innovation program (H2020-EU.3.1.1. - Understanding health, wellbeing and disease, H2020-EU.3.1.3. Treating and managing disease: Grant 945151, HORIZON.2.1.1 - Health throughout the Life Course: Grant 101057454 and EIT Health (EDIT-B project). DHM gratefully acknowledges the support of the Spanish Ministry of Health, Instituto de Salud Carlos III (PI049759) and the Pons-Bartran Legacy grant 2024 (FCRB_IPB1_2024). GA thanks the support of the Spanish Ministry of Science, Innovation and Universities financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Social Fund+ (ESF+) (JR23/00050, MV22/00058, CM21/00017); the ISCIII (PI24/00584, PI24/01051, PI21/00340, PI21/00169); the Milken Family Foundation (PI046998); the Fundació Clínic per a la Recerca Biomèdica (FCRB) – Pons Bartan 2020 grant (PI04/6549), the Sociedad Española de Psiquiatría y Salud Mental (SEPSM); the Fundació Vila Saborit; the Societat Catalana de Psiquiatria i Salut Mental (SCPiSM); and the Translational Research Programme for Brain Disorders, IDIBAPS. IG has received support from the Spanish Ministry of Science, Innovation and Universities (MCIN) (PI23/00822) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación and European Union (FEDER, FSE, Next Generation EU/Plan de Recuperación Transformación y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); and Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme/Generalitat de Catalunya as well as the Fundació Clínic per la Recerca Biomèdica (Pons Bartran 2022-FRCB_PB1_2022). SM has received support from the “Fundacio Clinic de Recerca Biomedica” through the Emili Letang-Josep Font Scholarship program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Awake Electrophysiological Profiling of the Ventromedial Prefrontal Cortex in a Mouse Model of Depression and Parkinson's Disease

  • Sancho-Alonso, María
  • Vila-Martín, Manuel Esteban
  • Teruel-Martí, Vicent
  • Bortolozzi, Analía
While Parkinson's disease (PD) is primarily known as a motor disorder, non-motor symptoms often emerge before motor deficits and significantly impact disease progression, being crucial at all disease stages. Among these, depression and anxiety are the most prevalent symptoms and cause a higher symptom burden in women than in men. Alterations in the serotonergic (5-HT) system are frequently linked to mood disorders, and accumulations of α-synuclein (α-Syn) have been observed in the 5-HT raphe nuclei (RN) of patients with Parkinson's disease (PD) and depression. Understanding the neural circuits underlying these non-motor symptoms is therefore critical. Here, we present an improved protocol to investigate the role of the ventromedial prefrontal cortex (vmPFC)-dorsal raphe nucleus (DR) circuit in PD-associated mood disorders using a female mouse model overexpressing the mutant A53T form of human α-syn (h-α-Syn) in the DR. Our method allows high-resolution assessment of neuronal activity in the infralimbic (IL) and prelimbic (PL) cortices under both basal conditions and during aversive conditioning and extinction. Using a tone-light sensory conditioning paradigm in awake, head-fixed mice, we employ multichannel electrophysiological probes to record neuronal responses. Experiments were conducted in virtual reality corridors, combining a cylindrical treadmill with a dual-screen visual display to maintain behavioral engagement while ensuring precise control of sensory stimuli and recording stability. This protocol builds on the established involvement of the IL and PL cortices in fear conditioning and extinction and provides a robust framework to examine dynamic neural activity in circuits implicated in depressive and anxiety-like behaviors in PD. By enabling simultaneous behavioral and electrophysiological measurements under controlled conditions, this approach offers a powerful tool for elucidating the neurobiological mechanisms of non-motor symptoms in PD and for testing potential interventions., This work has been funded by the 2023 BBRF Young Investigator Grant 31547 (MSA), MCIU/AEI/FEDER EU grant PID2022-141700OB-I00, MCIN/AEI/10. 13039/501100011033 (AB), AGAUR 2021-SGR-01358, Government of Catalonia (AB), and PID2022-141733NB-I00 (VT). We would also like to thank the Spanish Network for Research on Stress, MCIN/ AEI/10.13039/501100011033 and CB/07/09/0034 Centre for Biomedical Research in Mental Health Network (CIBERSAM). MSA has a Margarita Salas Scholarship (MS21-132) from the University of Valencia (reclassification of the Spanish University System of the Ministry of Universities of the Government of Spain, financed by the European Union, Next Generation EU)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Age-stratified associations between severe mental illness, dementia, and ischemic stroke: findings from the PADRIS-PRESTO cohort

  • De Prisco, Michele
  • Oliva, Vincenzo
  • Sanchez-Valle, Raquel
  • Parellada, Eduard
  • Junque, Carme
  • Marti, Maria J.
  • Bortolozzi, Analía
  • Alberch, Jordi
  • Garrabou, Gloria
  • Sanchez-Vives, Maria V.
  • Giralt, Albert
  • Segura, Barbara
  • Lladó, Albert
  • Compta, Yaroslau
  • Radua, Joaquim
  • Vieta, Eduard
  • Hidalgo-Mazzei, Diego
  • Anmella, Gerard
People with severe mental illnesses (SMIs), including schizophrenia spectrum disorders (SSD), major depressive disorder (MDD), and bipolar disorder (BD), experience elevated rates of physical comorbidity and premature mortality. Dementia and ischemic stroke contribute substantially to this burden, yet age-specific patterns of these associations remain poorly characterized. To bridge this gap, we conducted a population-based cross-sectional study using the PADRIS-PRESTO cohort, integrating primary and specialized care records from the Catalan public health system (Spain). Adults with a lifetime SMI diagnosis were compared with controls without any psychiatric condition. Weighted age-stratified prevalence was calculated and logistic regression models estimated age-specific odds ratios (ORs) with 95% confidence intervals (CIs), adjusting for socioeconomic status and medical comorbidity burden. Among 694,086 participants, 176,870 had an SMI diagnosis. Dementia prevalence was 3.49% (range, 0.33% at ages 20-29 to 39.51% at 90-99 years) in SMIs and 0.36% (0.02%-17.7%) in controls. Ischemic stroke prevalence was 5.3% (0.22%-16.4%) in SMIs and 2.75% (0.08%-14.67%) in controls. The ORs between SMI and dementia were significant across all age groups, with the strongest association observed at younger ages (OR = 23.21, 95% CIs = 13.74-39.19 at 30-39 years). Elevated ORs for stroke persisted up to 70-79 years, peaking at 40-49 years (OR = 2.99, 95% CIs = 2.63-3.41). Patterns were consistent across SMI subtypes. These findings highlight the need for earlier and more systematic neurological and cardiometabolic screening and management within psychiatric care and support policies that recognize SMIs as risk factors for vascular diseases and dementia., Michele De Prisco is supported by the Translational Research Programme for Brain Disorders, IDIBAPS. Vincenzo Oliva thanks the support of the Spanish Ministry of Science, Innovation and Universities financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Social Fund+ (ESF+) (CM24/00143, MV25/00042). Carme Junque thanks the Spanish Ministry of Economy and Competitiveness (MINECO PID2020-114640GB-I00/ and PID2023-146932NB-I00 financed by MICIU/AEI/ 110.13039/5011000111033/FEDER, UE); Generalitat de Catalunya (SGR 2021SGR00801); María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona) CEX2021001159-M, Ministry of Science and Innovation; and La Marato 202225-31358/U/2022. Analia Bortolozzi thanks the Spanish Ministry of Economy and Competitiveness (MCIU/AEI/FEDER, UE grant PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033); La Marató de TV3 Foundation 202207-30; and Caixa Research Health - HR25-00556. Jordi Alberch is supported by a grant from Ministerio de Ciencia e Innovación/AEI/https://doi.org/10.13039/501100011033/ and “FEDER” (PID2024-157024OB-I00). Gloria Garrabou is supported by The Catalan Government (2021-SGR-01423), and Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III (PI24/00428) and CIBERER, both initiatives of ISCIII and FEDER, co-funded by the European Union. Maria V. Sanchez-Vives is funded by the European Union (ERC, NEMESIS, project number 101071900). Albert Giralt is supported by a grant from Ministerio de Ciencia e Innovación/AEI/https://doi.org/10.13039/501100011033/ and “FEDER” (PID2020-119386RB-I00). Barbara Segura thanks the Spanish Ministry of Economy and Competitiveness (PID2023-146932NB-I00 financed by MICIU/AEI/ 110.13039/5011000111033/FEDER, UE); Generalitat de Catalunya (SGR 2021SGR00801); María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona) CEX2021001159-M, Ministry of Science and Innovation; and La Marato 202225-31358/U/2022. Joaquim Radua thanks the support of the Spanish Ministry of Science, Innovation and Universities (CPII19/00009, PI22/00261, PI25/01463) integrated into the Plan Nacional de I + D+I and co-financed by the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) and the Instituto de Salud Carlos III; and the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021-SGR-01128). Eduard Vieta thanks the support of the Spanish Ministry of Science, Innovation and Universities (PI21/00787, PI24/00432) integrated into the Plan Nacional de I+D+I and co-financed by the Instituto de Salud Carlos III -Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER); the Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme, Generalitat de Catalunya; La Marató-TV3 Foundation grants 202234-30; the European Union Horizon 2020 research and innovation program (H2020-EU.3.1.1. - Understanding health, wellbeing and disease, H2020-EU.3.1.3. Treating and managing disease: Grant 945151, HORIZON.2.1.1 - Health throughout the Life Course: Grant 101057454 and EIT Health (EDIT-B project). Diego Hidalgo-Mazzei gratefully acknowledges the support of the Spanish Ministry of Health, Instituto de Salud Carlos III (PI049759) and the Pons-Bartran Legacy grant 2024 (FCRB_IPB1_2024). Gerard Anmella thanks the support of the Spanish Ministry of Science, Innovation and Universities financed by the Instituto de Salud Carlos III (ISCIII) and co-financed by the European Social Fund+ (ESF+) (JR23/00050, MV22/00058, CM21/00017); the ISCIII (PI24/00584, PI24/01051, PI21/00340, PI21/00169); the Milken Family Foundation (PI046998); the Fundació Clínic per a la Recerca Biomèdica (FCRB) - Pons Bartan 2020 grant (PI04/6549), the Sociedad Española de Psiquiatría y Salud Mental (SEPSM); the Fundació Vila Saborit; the Societat Catalana de Psiquiatria i Salut Mental (SCPiSM); and the Translational Research Programme for Brain Disorders, IDIBAPS. IG has received support from the Spanish Ministry of Science, Innovation and Universities (MCIN) (PI23/00822) integrated into the Plan Nacional de I+D+I and cofinanced by the ISCIII-Subdirección General de Evaluación and European Union (FEDER, FSE, Next Generation EU/Plan de Recuperación Transformación y Resiliencia_PRTR); the Instituto de Salud Carlos III; the CIBER of Mental Health (CIBERSAM); and Generalitat de Catalunya and Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2021 SGR 01128), CERCA Programme / Generalitat de Catalunya as well as the Fundació Clínic per la Recerca Biomèdica (Pons Bartran 2022-FRCB_PB1_2022)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Early synaptic changes and reduced brain connectivity in PD-like mice with depressive phenotype

  • Miquel-Rio, Lluis
  • Jericó-Escolar, Judith
  • Sarriés-Serrano, Unai
  • Yanes-Castilla, Claudia
  • Torres-López, María
  • Argibay, Uxia
  • Paz, Verónica
  • Casal, Carmen
  • Muñoz-Moreno, Emma
  • López-Gil, Xavier
  • Bortolozzi, Analía
Anxiety and depression are common in Parkinson’s disease (PD), affecting quality of life. Aggregates of α-synuclein (α-Syn) are found in serotonergic (5-HT) raphe nuclei early in the disease, but their relationship to brain changes is unclear. We investigated synaptic plasticity, neuronal activity, and functional magnetic resonance imaging (fMRI)-based brain connectivity in a PD-like mouse model with depressive phenotype. AAV-induced human α-Syn accumulation in raphe 5-HT neurons causes progressive synaptic pathology in interconnected brain regions. This is marked by lower MAP-2, PSD95 and higher SV2A, VAMP2, which are key to synaptic structure and function, as confirmed in human brain tissue samples. Abnormalities in Egr-1-dependent neuronal activity and region-specific differences in resting-state functional brain activity were also detected eight weeks post-AAV infusion, before neurodegeneration. This provides evidence for synaptic and fMRI markers associated with α-Syn pathology in emotional brain circuits, and has translational importance for identifying PD patients at risk for depression., This work was supported by MCIU/AEI/FEDER, UE grant (PID2019-105136RB-100, PID2022-141700OB-I00, MCIN/AEI/10.13039/501100011033 to A.B.), and AGAUR 2021-SGR-01358, Catalan Government. CB/07/09/0034 Center for Networked Biomedical Research on Mental Health (CIBERSAM). We also thank the Spanish Stress Research Network, MCIN/AEI/10.13039/501100011033. U.S.S. is a recipient of a fellowship from the Non- Doctor Researcher Formation Pre-doctoral Program of Basque Government, Spain. U.A. is a recipient of a fellowship from the State Research Agency for the training of predoctoral research personnel (PREP2022-000676) associated to a generation of knowledge project (PID2022-141700OB-I00). The authors would like to thank the staff members of the Biobank of the Clinic Hospital Barcelona - IDIBAPS for their collaboration in the study.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Restoration of CB1 receptor function in hippocampal GABAergic neurons rescues memory deficits in Huntington's disease models

  • Franco, Nadia Di
  • Bengoetxea de Tena, Iker
  • Sanchez-Ruiz, Andrea
  • Pereda-Velarde, Alba
  • Enfedaque, Ferran
  • González-Arias, Candela
  • Miquel-Rio, Lluis
  • Bortolozzi, Analía
  • Rodríguez-Puertas, Rafael
  • Costas-Insua, Carlos
  • Molina-Porcel, Laura
  • Vázquez-Oliver, Anna
  • Ozaita Mintegui, Andrés, 1969-
  • Guzmán, Manuel
  • Perea, Gertrudis
  • Ginés, Silvia
Background: Dysregulation of the endocannabinoid system (eCBS) and the loss of CB1 receptors (CB1R) in the basal ganglia are well-established hallmarks of Huntington's disease (HD). As a result, significant research efforts have focused on targeting the eCBS to alleviate motor disturbances associated with the disease. Beyond its role in motor control, the eCBS is a complex signaling network critically involved in regulating learning and memory. Despite this, the potential involvement of eCBS dysfunction in the cognitive decline characteristic of HD, often manifested well before motor dysfunction, has remained largely unexplored. Methods: CB1R expression in the hippocampus was evaluated in both human HD samples and HD mouse models (R6/1 and Hdh models, including both sexes) using Western blotting, immunohistochemistry, and radioligand binding assays. To restore CB1R function, CB1R agonist WIN-55212-2 was systemically administered, or viral vectors encoding CB1R were locally infused into the hippocampus of HD mice. A multidisciplinary approach combining behavioral, biochemical, electrophysiological, and morphological analyses, was employed to investigate the molecular mechanisms underlying the effects of CB1R activation in the context of HD-related cognitive dysfunction. Results: In both human HD samples and HD mouse models, CB1R protein levels were reduced in the hippocampus, accompanied by structural synaptic alterations and impairment in spatial, recognition and working memory. Moreover, hippocampal depolarization-induced suppression of inhibition was significantly disrupted in R6/1 mice. Administration of WIN-55212-2 successfully restored these synaptic and cognitive deficits. Immunohistochemical analysis revealed that the CB1R decrease was specifically localized to GABAergic interneurons within the hippocampus. Notably, targeted restoration of CB1R expression in these interneurons via viral vector delivery was sufficient to rescue hippocampal-dependent memory deficits in HD mice. Conclusion: This study suggests that impaired CB1R function in hippocampal GABAergic interneurons contributes to memory dysfunction in HD., This work was supported by the Spanish Ministerio de Ciencia e Innovación (PID2021-123732OB-I00 to SG, PID2021-125118OB-I00 to MG, PID2019-106579RB-I00, and PID2022-142617NB-I00 to GP, and PID2022-141700OB-I00 to AB funded by MCIN/AEI/ https://doi.org/10.13039/501100011033). Fundació la Marató de TV3 (202013-30-31-32 to SG, MG and GP), AGAUR Generalitat de Catalunya (2021-SGR-01358 to AB and 2021-SGR 01086 to SG) and grants to R. R.-P. rom the Basque Government IT1454-22 to the "Neurochemistry and Neurodegeneration" consolidated research group; Instituto de Salud Carlos III through the project PI20/00153 (co-funded by European Regional Development Fund "A way to make Europe") and by BIOEF through the project BIO22/ALZ/010 funded by Eitb Maratoia. A P-V is the recipient of a PRE2022-101764 fellowship (PID2021-123732OB-I00). I.B.d.T. is the recipient of an Investigo fellowship funded by the European Union-Next Generation EU.